First Patient Dosed in Phase 2b/3 NAAVIGATE Trial of Gene Therapy Surabgene Lomparvovec in Diabetic Retinopathy

CGTLive®·Jul 7

✦ NabkaNews BriefAuto-summarized from multiple outlets · verify with the source

A phase 2b/3 trial, known as NAAVIGATE, has begun dosing patients to test the gene therapy surabgene lomparvovec in treating diabetic retinopathy. The trial's status is confirmed by multiple reports of the first patient being dosed. However, details about the trial's progress and outcomes are not available in the provided reports, which also mention unrelated trials and therapies for other conditions.

Full coverage

RegenxBio doses first patient in phase 2b/3 trial for DR

Eyes On Eyecare·Jul 10

Pivotal Trial for Taysha's Rett Syndrome Gene Therapy TSHA-102 Doses First Patient

CGTLive®·Jan 30

Patients Treated With AskBio’s Limb-Girdle Muscular Dystrophy Gene Therapy AB-1003 Free of Serious Adverse Events at Up to 52 Weeks

CGTLive®·Oct 17

First Patient Dosed in Phase 2/3 GARDian3 Trial of OCU410ST for Stargardt Disease

CGTLive®·Jul 24

Around the Helix: Cell and Gene Therapy Company Updates – May 20, 2026

CGTLive®·May 20

Ocugen’s Gene Therapy OCU410ST Continues to Show Efficacy in Phase 1 Stargardt Disease Trial

CGTLive®·Jan 29

Around the Helix: Cell and Gene Therapy Company Updates – April 1, 2026

CGTLive®·Apr 1

Ocugen Posts Positive Preliminary Phase 2 ArMaDa Trial Data of OCU410

CGTLive®·Jan 20

View original report at CGTLive® ↗

Fetching the latest headlines…